AI
TEVA icon

Accredited Investors’s Teva Pharmaceuticals TEVA Stock Holding History

Accredited Investors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,550
Closed -$284K – 124
2017
Q2 		$284K Hold
8,550
– – 0.07% 77
2017
Q1 		$274K Sell
8,550
-340
-4% -$11.6K 0.07% 83
2016
Q4 		$322K Buy
8,890
+340
+4% +$13.6K 0.08% 73
2016
Q3 		$393K Hold
8,550
– – 0.11% 65
2016
Q2 		$429K Hold
8,550
– – 0.12% 62
2016
Q1 		$458K Hold
8,550
– – 0.12% 60
2015
Q4 		$562K Buy
+8,550
New +$528K 0.14% 48

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Accredited Investors's TEVA Position: Q3 2017 in Review

Accredited Investors sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 8,550 shares — an estimated $284K sold.

Accredited Investors first reported a position in TEVA in Q4 2015 and held it in 7 quarters. The position peaked at $562K in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Accredited Investors reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Accredited Investors sold 8,550 Teva Pharmaceuticals shares in Q3 2017, an estimated $284K.
  • Accredited Investors first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 7 quarters.
  • Accredited Investors's Teva Pharmaceuticals position peaked at $562K in Q4 2015.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Accredited Investors's 13F filing for Q3 2017, filed 30 Oct 2017.